SOURCE: Hutchison China Meditech Limited

December 14, 2016 03:05 ET

Hutchison China Meditech Limited: Director's Share Dealing

HONG KONG, CHINA--(Marketwired - Dec 14, 2016) - Hutchison China Meditech Limited (AIM: HCM) (NASDAQ: HCM)

Director's Share Dealing

London: Wednesday, December 14, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med ("Ordinary Share")) at an average price of US$14.18 per ADS on December 9, 2016, December 12, 2016 and December 13, 2016. 

Following the above purchase of 52,161 ADSs, Mr To is interested in 52,161 ADSs and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in a family trust of which his family members are the beneficiaries), representing approximately 0.34% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation. 

   
1 Details of the person discharging managerial responsibilities/person closely associated

a)

Name
 
Mr Simon To
2 Reason for the notification

a)

Position/status
 
Executive Director and Chairman

b)

Initial notification/Amendment
 
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name
 
Hutchison China MediTech Limited

b)

LEI
 
N/A
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument
Identification code
 
ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035

b)

Nature of the transaction
 
Acquisition of ADSs

c)

Price(s) and volume(s)
   
Price(s) Volume(s)
US$14.05 10,000
   
 

d)

Aggregated information
 
N/A
- Aggregated volume  
- Price  
   

e)

Date of the transaction
 
2016-12-09

f)

Place of the transaction
 
Nasdaq Stock Market
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument
Identification code
 
ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035

b)

Nature of the transaction
 
Acquisition of ADSs

c)

Price(s) and volume(s)
   
Price(s) Volume(s)
US$14.12 30,000
   
 

d)

Aggregated information
 
N/A
- Aggregated volume  
- Price  
   

e)

Date of the transaction
 
2016-12-12

f)

Place of the transaction
 
Nasdaq Stock Market
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument
Identification code
 
ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035

b)

Nature of the transaction
 
Acquisition of ADSs

c)

Price(s) and volume(s)
   
Price(s) Volume(s)
US$14.43 12,161
   
 

d)

Aggregated information
 
N/A
- Aggregated volume  
- Price  
   

e)

Date of the transaction
 
2016-12-13

f)

Place of the transaction
 
Nasdaq Stock Market
       

About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

         
Investor Enquiries        
Christian Hogg, CEO   +852 2121 8200    
         
International Media Enquiries        
Anthony Carlisle,
Citigate Dewe Rogerson
  +44 7973 611 888 (Mobile)   anthony.carlisle@cdrconsultancy.co.uk
         
U.S. Based Media Enquiries        
Brad Miles, BMC Communications   +1 (917) 570 7340 (Mobile)   bmiles@bmccommunications.com
         
Susan Duffy, BMC Communications   +1 (917) 499 8887 (Mobile)   sduffy@bmccommunications.com
         
Investor Relations        
Matt Beck, The Trout Group   +1 (917) 415 1750 (Mobile)   mbeck@troutgroup.com
         
David Dible,
Citigate Dewe Rogerson
  +44 7967 566 919 (Mobile)   david.dible@citigatedr.co.uk
         
Panmure Gordon (UK) Limited        
Richard Gray / Andrew Potts   +44 (20) 7886 2500    
         

Contact Information